Log in
Pulmonary vasodilator

Nitric oxide

Nitric oxide is an inhaled selective pulmonary vasodilator used primarily in neonates with hypoxic respiratory failure and persistent pulmonary hypertension of the newborn (PPHN). It acts via cyclic GMP-mediated smooth muscle relaxation. The most testable fact is that methemoglobinemia is the classic dose-dependent adverse effect requiring monitoring.

Practice questionsHigh-yield facts
Drug classInhaled pulmonary vasodilator
MechanismActivates guanylate cyclase, increases cGMP, relaxes pulmonary smooth muscle
Main usesPersistent pulmonary hypertension of the newborn (PPHN)
Key adverse effectMethemoglobinemia (dose-dependent)
5 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Nitric oxide is an endogenous signaling molecule that acts as a potent vasodilator. When inhaled, it diffuses across the alveolar-capillary membrane and binds to the heme moiety of soluble guanylate cyclase in pulmonary vascular smooth muscle cells.

This binding activates guanylate cyclase, which catalyzes the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). Increased intracellular cGMP leads to activation of protein kinase G, which phosphorylates downstream targets that reduce intracellular calcium and promote smooth muscle relaxation.

The selectivity for pulmonary vasculature occurs because inhaled nitric oxide is rapidly inactivated upon contact with hemoglobin in the bloodstream, forming methemoglobin and nitrate. This inactivation prevents systemic vasodilation and limits effects to the pulmonary circulation. The drug improves ventilation-perfusion matching by dilating vessels in well-ventilated alveolar units, thereby reducing intrapulmonary shunting and improving oxygenation.

High-yield for exams
  • Nitric oxide activates guanylate cyclase, increasing cGMP and causing selective pulmonary vasodilation.
  • Methemoglobinemia is the classic dose-dependent adverse effect; levels above 5% require dose reduction.
  • Rapidly inactivated by hemoglobin in blood, preventing systemic vasodilation.
  • Rebound pulmonary hypertension occurs with abrupt discontinuation; always taper gradually.
  • Nitrogen dioxide (NO₂) is a toxic byproduct; inspired levels must be monitored and kept below 5 ppm.
  • Improves oxygenation in PPHN by reducing right-to-left shunting through the ductus arteriosus and foramen ovale.
  • Contraindicated in neonates dependent on right-to-left shunting (e.g., hypoplastic left heart syndrome).
  • Sildenafil (PDE-5 inhibitor) can potentiate effects and facilitate weaning from nitric oxide.

Indications

The primary FDA-approved indication is:

  • Persistent pulmonary hypertension of the newborn (PPHN) in term and near-term neonates with hypoxic respiratory failure

PPHN occurs when pulmonary vascular resistance fails to decrease after birth, leading to right-to-left shunting through the foramen ovale and ductus arteriosus, resulting in severe hypoxemia. Nitric oxide therapy improves oxygenation and reduces the need for extracorporeal membrane oxygenation (ECMO) in this population.

Off-label uses

While not FDA-approved, nitric oxide is used off-label in:

  • Acute respiratory distress syndrome (ARDS) to improve oxygenation temporarily
  • Pulmonary hypertension associated with cardiac surgery
  • Right ventricular failure in adults
  • Donor lung preservation and assessment for transplantation

Evidence for off-label uses is mixed, and these applications remain investigational in many contexts.

Pharmacokinetics

Route of administration: Nitric oxide is administered exclusively by inhalation through a ventilator circuit or delivery system specifically designed for this purpose.

Absorption and distribution: The drug is rapidly absorbed across the alveolar-capillary membrane. It acts locally in the pulmonary vasculature before reaching systemic circulation.

Metabolism: Nitric oxide is rapidly inactivated in the bloodstream by binding to hemoglobin. This produces methemoglobin and nitrate. Methemoglobin is subsequently reduced back to hemoglobin by methemoglobin reductase. Nitrate is the principal metabolite and is eliminated renally.

Elimination: The half-life of nitric oxide in blood is extremely short, measured in seconds. Nitrate metabolites are cleared by the kidneys with a half-life of approximately 5 to 6 hours.

Special populations: Renal impairment may lead to accumulation of nitrate metabolites, though clinical significance is limited given the short duration of therapy in neonates.

Adverse effects

Common adverse effects

  • Methemoglobinemia (dose-dependent): the most important adverse effect; occurs when more than 1-2% of hemoglobin is oxidized to methemoglobin, which cannot carry oxygen. Levels above 5% require dose reduction or discontinuation. Monitoring is mandatory during therapy.
  • Rebound pulmonary hypertension: abrupt withdrawal can cause sudden increases in pulmonary artery pressure and worsening hypoxemia; tapering is essential.

Serious adverse effects

  • Nitrogen dioxide toxicity: nitric oxide reacts with oxygen to form nitrogen dioxide (NO₂), a toxic oxidant that can cause pulmonary edema and airway injury. Inspired NO₂ concentrations must be monitored and kept below 5 ppm.
  • Thrombocytopenia: mild and reversible platelet suppression has been observed.
  • Increased bleeding risk: theoretical concern due to inhibition of platelet aggregation, though clinically significant bleeding is rare.

Other considerations

Systemic hypotension is uncommon due to rapid inactivation, but can occur with delivery system malfunction or excessive dosing.

Contraindications and warnings

Contraindications

  • Neonates dependent on right-to-left shunting: infants with certain congenital heart defects where pulmonary blood flow depends on shunting (e.g., hypoplastic left heart syndrome, critical aortic stenosis) may deteriorate with pulmonary vasodilation.

Warnings and precautions

  • Methemoglobin monitoring: methemoglobin levels must be measured within 1 hour of initiating therapy and periodically thereafter. Levels exceeding 5% warrant dose reduction.
  • Nitrogen dioxide monitoring: continuous monitoring of inspired NO₂ is required; levels above 5 ppm necessitate adjustment of the delivery system or dose reduction.
  • Abrupt discontinuation: rebound pulmonary hypertension can be life-threatening. Gradual weaning over 30 minutes to several hours is recommended.
  • Heart failure: patients with left ventricular dysfunction may develop pulmonary edema if pulmonary vascular resistance drops suddenly.
  • Pregnancy category: not applicable for neonatal use, but animal studies suggest potential fetal harm; use in pregnant women is not established.

Drug interactions

  • Phosphodiesterase-5 inhibitors (sildenafil, tadalafil): concurrent use enhances cGMP-mediated vasodilation and may potentiate hypotension or improve weaning from nitric oxide in some cases. This combination is sometimes used intentionally but requires careful monitoring.
  • Nitrates and nitric oxide donors (nitroglycerin, nitroprusside): theoretical additive effects on methemoglobin formation and vasodilation.
  • Prilocaine and other drugs causing methemoglobinemia: increased risk of clinically significant methemoglobinemia when combined with nitric oxide.
  • Oxygen: high concentrations of supplemental oxygen increase the formation of nitrogen dioxide from nitric oxide, raising the risk of NO₂ toxicity.

No significant cytochrome P450 interactions exist because nitric oxide does not undergo hepatic metabolism.

Clinical pearls

  • Nitric oxide improves oxygenation in PPHN by reducing right-to-left shunting, not by treating the underlying lung disease.
  • Always taper gradually; even brief interruptions can precipitate rebound pulmonary hypertension.
  • Methemoglobin levels must be monitored—this is a high-yield exam point. Methemoglobinemia above 5% requires intervention.
  • Nitrogen dioxide is a toxic byproduct; delivery systems must monitor NO₂ levels continuously.
  • The drug does not improve mortality in ARDS but may transiently improve oxygenation as a bridge to other therapies.
  • Use specialized delivery systems calibrated for low concentrations (typically 5-20 ppm in neonates).
  • Sildenafil is sometimes used to facilitate weaning from inhaled nitric oxide by maintaining pulmonary vasodilation via the same cGMP pathway.
  • In ventilated patients, ensure adequate alveolar ventilation; nitric oxide is ineffective in atelectatic or unventilated lung regions.
  • Black box warning: abrupt discontinuation may lead to worsening oxygenation and cardiovascular collapse.
Mnemonic

NO GAS: Nitric Oxide → Guanylate cyclase Activated → Smooth muscle relaxation

Practice questions

1. A full-term newborn develops severe cyanosis 6 hours after birth. Physical examination reveals tachypnea and a single loud S2. Echocardiography shows elevated pulmonary artery pressure with right-to-left shunting across the foramen ovale and ductus arteriosus, but no structural cardiac defects. The infant is intubated and started on inhaled nitric oxide at 20 ppm. Which of the following laboratory parameters must be monitored closely during this therapy?

Answer: B. Methemoglobin level must be monitored because nitric oxide oxidizes hemoglobin to methemoglobin, which cannot carry oxygen. Levels above 5% require dose reduction. This is a dose-dependent adverse effect and a key monitoring parameter in all patients receiving inhaled nitric oxide. The clinical scenario describes persistent pulmonary hypertension of the newborn (PPHN), the primary indication for nitric oxide therapy.

2. A 3-day-old neonate with persistent pulmonary hypertension has been receiving inhaled nitric oxide at 10 ppm with good response. Due to a mechanical malfunction, the nitric oxide delivery is abruptly interrupted for 5 minutes. Shortly after, the infant develops worsening hypoxemia and cyanosis despite maximal ventilatory support. Which of the following best explains this clinical deterioration?

Answer: B. Rebound pulmonary hypertension occurs when nitric oxide is abruptly discontinued. The sudden loss of pulmonary vasodilation causes a rapid increase in pulmonary vascular resistance, worsening right-to-left shunting and hypoxemia. This is why nitric oxide must always be weaned gradually. Nitrogen dioxide toxicity would develop during administration, not after discontinuation, and methemoglobin levels would not rise acutely after stopping the drug.

3. A neonate receiving inhaled nitric oxide for persistent pulmonary hypertension is noted to have an inspired nitrogen dioxide (NO₂) concentration of 7 ppm on routine monitoring. Methemoglobin level is 2.5%. Which of the following is the most appropriate next step in management?

Answer: C. Inspired nitrogen dioxide levels above 5 ppm indicate excessive NO₂ formation, which is toxic and can cause airway injury and pulmonary edema. The appropriate response is to reduce the nitric oxide dose or adjust the delivery system to lower NO₂ production. Methemoglobin level is normal (below 5%), so methylene blue is not indicated. Abrupt discontinuation would risk rebound pulmonary hypertension. Increasing oxygen would worsen NO₂ formation because nitric oxide reacts with oxygen to form nitrogen dioxide.

Frequently asked questions

How does nitric oxide work?

Nitric oxide works by diffusing into pulmonary vascular smooth muscle cells and activating soluble guanylate cyclase. This increases cyclic GMP (cGMP), which causes smooth muscle relaxation and vasodilation. Because nitric oxide is rapidly inactivated by hemoglobin in the bloodstream, its effects are selective for the pulmonary circulation, improving oxygenation without causing systemic hypotension.

What are the side effects of nitric oxide?

The most important side effect is methemoglobinemia, a dose-dependent condition where hemoglobin is oxidized and cannot carry oxygen; levels above 5% require dose reduction. Other adverse effects include rebound pulmonary hypertension if abruptly discontinued, nitrogen dioxide toxicity from the byproduct NO₂, and rarely thrombocytopenia or bleeding. Continuous monitoring of methemoglobin and NO₂ levels is mandatory during therapy.

What is nitric oxide used for?

Nitric oxide is FDA-approved for treating persistent pulmonary hypertension of the newborn (PPHN) in term and near-term neonates with hypoxic respiratory failure. It improves oxygenation and reduces the need for ECMO by selectively dilating pulmonary vessels. Off-label uses include ARDS, pulmonary hypertension during cardiac surgery, and right ventricular failure, though evidence for these indications is less robust.

Can nitric oxide be stopped suddenly?

No, nitric oxide should never be stopped abruptly. Sudden discontinuation causes rebound pulmonary hypertension, with rapid increases in pulmonary artery pressure and severe worsening of oxygenation, potentially leading to cardiovascular collapse. The drug must be tapered gradually over 30 minutes to several hours, and some patients are transitioned to oral sildenafil to maintain pulmonary vasodilation during weaning.

Nitric oxide vs sildenafil—what is the difference?

Nitric oxide is an inhaled gas that directly activates guanylate cyclase in pulmonary smooth muscle, causing immediate selective pulmonary vasodilation. Sildenafil is an oral phosphodiesterase-5 inhibitor that prevents breakdown of cGMP, prolonging the vasodilatory signal. Nitric oxide acts within seconds but requires continuous inhalation; sildenafil has a slower onset but longer duration and is sometimes used to facilitate weaning from inhaled nitric oxide.

Conditions it is used for

Persistent pulmonary hypertension of the newbornHypoxic respiratory failure in neonatesAcute respiratory distress syndromePulmonary hypertensionRight ventricular failure
SildenafilEpoprostenolBosentanTadalafilIloprostRiociguatAmbrisentanMacitentan

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: R07AX01

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.